The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension were developed by the task force of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), and endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). These guidelines provide comprehensive recommendations for the diagnosis, classification, and management of pulmonary hypertension (PH), which is classified into five groups based on underlying causes. The guidelines emphasize a multidisciplinary approach, involving cardiologists, pneumologists, surgeons, and patients, to ensure effective management of PH. They include detailed diagnostic algorithms, treatment strategies, and risk stratification tools for different PH subgroups. The guidelines also address specific subsets of PH, such as those associated with left heart disease, lung disease, chronic thrombo-embolic pulmonary hypertension, and connective tissue diseases. The recommendations are based on a systematic review of the available evidence, using the GRADE Evidence to Decision framework, and are intended to guide clinical practice in both cardiology and respiratory medicine. The guidelines highlight the importance of early detection, appropriate use of medications, and the role of multidisciplinary teams in managing PH. They also emphasize the need for patient education, adherence to treatment, and the importance of considering individual patient factors when making clinical decisions. The guidelines are freely available for use by health professionals and are regularly updated to reflect the latest scientific and medical knowledge.The 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension were developed by the task force of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), and endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). These guidelines provide comprehensive recommendations for the diagnosis, classification, and management of pulmonary hypertension (PH), which is classified into five groups based on underlying causes. The guidelines emphasize a multidisciplinary approach, involving cardiologists, pneumologists, surgeons, and patients, to ensure effective management of PH. They include detailed diagnostic algorithms, treatment strategies, and risk stratification tools for different PH subgroups. The guidelines also address specific subsets of PH, such as those associated with left heart disease, lung disease, chronic thrombo-embolic pulmonary hypertension, and connective tissue diseases. The recommendations are based on a systematic review of the available evidence, using the GRADE Evidence to Decision framework, and are intended to guide clinical practice in both cardiology and respiratory medicine. The guidelines highlight the importance of early detection, appropriate use of medications, and the role of multidisciplinary teams in managing PH. They also emphasize the need for patient education, adherence to treatment, and the importance of considering individual patient factors when making clinical decisions. The guidelines are freely available for use by health professionals and are regularly updated to reflect the latest scientific and medical knowledge.